Chiesi Expands Evidence Base for EB Treatment with New PeDRA Data
Event summary
- Chiesi presented new data on FILSUVEZ (birch triterpenes) at the 2026 PeDRA Annual Conference, expanding real-world evidence for epidermolysis bullosa (EB) treatment.
- Three presentations covered mechanistic research and clinician-reported real-world experience, including combination therapy approaches.
- FILSUVEZ was approved by the FDA in December 2023 and by European regulators in 2022 for treating EB-related wounds.
- Chiesi acquired KalVista Pharmaceuticals in 2026 to strengthen its rare disease portfolio.
The big picture
Chiesi’s presentation at PeDRA underscores its commitment to advancing EB treatment through real-world evidence, a critical strategy in the rare disease space where long-term clinical data is scarce. The company’s acquisition of KalVista further solidifies its position in rare disease therapeutics, aligning with broader industry trends toward targeted, innovative treatments for underserved patient populations.
What we're watching
- Regulatory Progress
- Whether Health Canada will approve FILSUVEZ in 2027, expanding its market reach in North America.
- Clinical Validation
- How additional real-world data will influence long-term adoption of FILSUVEZ in pediatric dermatology.
- Strategic Integration
- The pace at which Chiesi integrates KalVista’s assets to bolster its rare disease pipeline.